Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: Unlocking long-term insights

Anti-recombinant human acid α-glucosidase (rhGAA) antibodies can develop in adult Pompe patients receiving enzyme replacement therapy (ERT), but their long-term impact on clinical treatment outcomes is currently unclear.